Patents by Inventor Rajinder Singh

Rajinder Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR MEASURING AND CONTROLLING METHANOL CONCENTRATION IN A METHANOL FUEL CELL
    Publication number: 20180159155
    Abstract: Methods for measuring and controlling the methanol concentration in a methanol fuel cell such as a direct methanol fuel cell or fuel cell stack are disclosed. Processors and memory storage containing programs which execute instructions to control the methanol concentration in the fuel cell or fuel cell stack are also disclosed.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 7, 2018
    Inventors: Md Opu, Rajinder Singh, Jeff Henderson, Aditya Koparkar
  • Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
    Publication number: 20180153912
    Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
    Type: Application
    Filed: July 17, 2017
    Publication date: June 7, 2018
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Somasekhar Bhamidipati, Rajinder Singh, Thomas Sun, Esteban Masuda
  • PROCESS FOR PREPARATION OF CINACALCET INTERMEDIATE AND CINACALCET HYDROCHLORIDE
    Publication number: 20180155270
    Abstract: The present invention provides one pot process for preparation of highly pure unsaturated cinacalcet hydrochloride (II) comprising: i) converting 3-(trifluromethyl) cinnamic acid (III) into 3-(3-(trifluoromethyl)phenyl)prop-2-en-1-ol (IV), ii) converting 3-(3-(trifluoromethyl)phenyl)prop-2-en-1-ol (IV) to compound (V), wherein R is Cl, Br, I, tosylate and mesylate, Formula (V) iii) reacting compound (V) with (R)-1-(1-Naphthyl) ethylamine (VI) in presence of base followed by treatment with hydrochloric acid. The present invention further provides conversion of unsaturated cinacalcet hydrochloride (II) to cinacalcet hydrochloride (I).
    Type: Application
    Filed: May 27, 2016
    Publication date: June 7, 2018
    Inventors: Vishal Gautam Gaikwad, Sadanand Nilkanth Patil, Rajinder Singh Siyan, Nandu Baban Bhise, Girij Pal Singh
  • Mantle phenotype detection in palm
    Patent number: 9984200
    Abstract: Methods, compositions, kits, and computer program code are provided for predicting somaclonal abnormality (e.g., a Mantled phenotype) in a plant and or sorting plants based on the predicted presence or absence of somaclonal abnormality.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: May 29, 2018
    Assignee: MALAYSIAN PALM OIL BOARD
    Inventors: Meilina Ong Abdullah, Ooi Siew Eng, Leslie Low Eng Ti, Rajinder Singh, Rajanaidu Nookiah, Ravigadevi Sambanthamurthi, Nan Jiang, Steven W. Smith, Nathan D. Lakey, Rob Martienssen, Jared Ordway, Michael Hogan
  • Pyrazole compounds and method for making and using the compounds
    Patent number: 9982000
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: May 29, 2018
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ryan Kelley, Hui Li, Thilo Heckrodt, Yan Chen, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
  • GDF-8 inhibitors
    Patent number: 9981944
    Abstract: Disclosed are 2,2?-bipyridyl compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, Z and n are as described herein. In certain embodiments, a compound disclosed herein inhibits GDF8, and can be used to treat disease by blocking GDF8 signaling.
    Type: Grant
    Filed: February 15, 2016
    Date of Patent: May 29, 2018
    Assignees: RIGEL PHARMACEUTICALS, INC, BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Pingyu Ding, Marina Gelman, Todd Kinsella, Rajinder Singh, Somasekhar Bhamidipati, Upender Velaparthi, Robert M. Borzilleri, Hasibur Rahaman, Jayakumar Sankara Warrier
  • MODULATORS OF CHEMOKINE RECEPTORS
    Publication number: 20180141934
    Abstract: Compounds are provided as chemokine inhibitors having the structure:
    Type: Application
    Filed: October 26, 2017
    Publication date: May 24, 2018
    Inventors: Xi CHEN, Dean R. DRAGOLI, Junfa FAN, Jaroslaw KALISIAK, Antoni KRASINSKI, Manmohan Reddy LELETI, Venkat MALI, Jeffrey McMAHON, Rajinder SINGH, Hiroko TANAKA, Ju YANG, Chao YU, Penglie ZHANG
  • COMPOUNDS AND METHOD FOR TREATING AUTOIMMUNE DISEASES
    Publication number: 20180141938
    Abstract: Compounds and embodiments of a method for treating and/or preventing autoimmune diseases are disclosed. The method includes administering to a subject having an autoimmune disease, such as an inflammatory bowel disease, a therapeutically effective amount of a compound according to formula I wherein X and Y independently are O or NR1; each R1 is independently H or C1-C6 alkyl; ring A is aryl; each R2 independently is H, alkyl, alkoxy, amide, cyano, halo, haloalkyl, hydroxyalkyl, heteroalkyl, heterocyclyl, sulfonyl, sulfonamide, or two R2 groups, taken together with the atom or atoms to which they are attached, combine to form a 4-10 membered ring system; p is 0, 1, 2, 3, or 4; R3 and R4 independently are H or C1-C6 alkyl; and R5 is halo, cyano, or C1-C6 alkyl.
    Type: Application
    Filed: January 19, 2018
    Publication date: May 24, 2018
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Rajinder Singh, Vanessa Taylor, Donald G. Payan
  • METHOD OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS
    Publication number: 20180140587
    Abstract: A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.
    Type: Application
    Filed: November 22, 2017
    Publication date: May 24, 2018
    Inventors: Zhenhua Miao, Thomas Schall, Rajinder Singh
  • TGF-Beta Inhibitors
    Publication number: 20180127426
    Abstract: Disclosed are imidazole and thiazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, A, Z, R1 and R? are as described herein. In certain embodiments, a compound disclosed herein inhibits TGF-?, and can be used to treat disease by blocking TGF-? signaling.
    Type: Application
    Filed: January 2, 2018
    Publication date: May 10, 2018
    Inventors: Todd Kinsella, Marina Gelman, Hui Hong, Ihab S. Darwish, Rajinder Singh, Jiaxin Yu, Robert M. Borzilleri, Upender Velaparthi, Peiying Liu, Chetan Darne, Hasibur Rahaman, Jayakumar Sankara Warrier
  • AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING
    Publication number: 20180111917
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Application
    Filed: October 25, 2017
    Publication date: April 26, 2018
    Inventors: Kin Tso, Hui Li, Yan Chen, Rose Yen, Vanessa Taylor, Thilo Heckrodt, Rajinder Singh, Simon Shaw
  • IRAK INHIBITORS AND METHOD FOR MAKING AND USING
    Publication number: 20180111923
    Abstract: Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Application
    Filed: October 25, 2017
    Publication date: April 26, 2018
    Inventors: Hui Li, Thilo Heckrodt, Yan Chen, Ryan Kelley, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
  • TGF-ß Inhibitors
    Publication number: 20180086764
    Abstract: Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, X, Z, m, p, and R2 are as described herein. In certain embodiments, a compound disclosed herein inhibits the activity of one or more members of the TGF-? superfamily, and can be used to treat disease by blocking such activity.
    Type: Application
    Filed: April 1, 2015
    Publication date: March 29, 2018
    Inventors: Marina Gelman, Todd Kinsella, Somasekhar Bhamidipati, Ihab Darwish, Rajinder Singh, Jiaxin Yu
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 9920041
    Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: March 20, 2018
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Thilo J. Heckrodt, Yan Chen, Darren John McMurtrie, Vanessa Taylor, Rajinder Singh, Pingyu Ding, Rose Yen
  • Fumarate Analogs and Uses Thereof
    Publication number: 20180071271
    Abstract: Aspects of the present disclosure include compounds that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: September 21, 2017
    Publication date: March 15, 2018
    Inventors: Matthew Duncton, Somasekhar Bhamidipati, Jiaxin Yu, Ihab Darwish, Rajinder Singh
  • Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds
    Publication number: 20180072756
    Abstract: The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.
    Type: Application
    Filed: March 24, 2017
    Publication date: March 15, 2018
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Ankush Argade, Hui Li, Somasekhar Bhamidipati, David Carroll, Catherine Sylvain, Jeffrey Clough, Holger Keim
  • 2,4-pyrimidinediamine compounds and their uses
    Patent number: 9913842
    Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: March 13, 2018
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander Rossi
  • Amine derivatives as potassium channel blockers
    Patent number: 9914702
    Abstract: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: March 13, 2018
    Assignees: Bionomics Limited, Merck Patent GmbH
    Inventors: Andrew Harvey, Agnes Bombrun, Rachel Cooke, Isabelle Jeanclaude-Etter, Nathan Kuchel, Jerome Molette, Jorgen Mould, Dharam Paul, Rajinder Singh, Cristina Donini, Veronique Colovray, Thomas Avery, Julia Crossman, Justin Ripper
  • Protein kinase C inhibitors and uses thereof
    Patent number: 9913843
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: March 13, 2018
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rao Kolluri, Esteban Masuda, Kin Tso, Salvador Alvarez, Thilo Heckrodt, Sacha Holland, Ryan Kelley, Matthew Duncton, Rajinder Singh, Darren McMurtrie
  • AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME
    Publication number: 20180057478
    Abstract: Disclosed are substituted pyridine compounds as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure wherein E, J, T, the ring system denoted by “B”, T, R3, R4, w and x are as described herein. In certain embodiments, a compound disclosed herein activates the AMPK pathway, and can be used to treat metabolism-related disorders and conditions.
    Type: Application
    Filed: May 23, 2017
    Publication date: March 1, 2018
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Dane Goff, Donald Payan, Rajinder Singh, Simon Shaw, David Carroll, Yasumichi Hitoshi